Background: Antiplatelet agents are used to prevent cardiovascular events; however,
treatment effects may differ in persons with chronic kidney disease (CKD) because …

Abstract The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative
(KDOQI) has provided evidence-based guidelines for hemodialysis vascular access since …

Background Antiplatelet agents are widely used to prevent cardiovascular events. The risks
and benefits of antiplatelet treatment may be different in people with chronic kidney disease …

CHF Congestive heart failure CKD Chronic kidney disease CO Cardiac output CO2 Carbon
dioxide CPR Cardiopulmonary recirculation CTA Computed tomography angiography CVD …

Objective: The aim of this study was to determine the bleeding risks associated with single
(aspirin) and dual (aspirin+ clopidogrel) antiplatelet therapy (DAPT) versus placebo or no …

In patients receiving hemodialysis, the provision of safe and effective vascular access using
an arteriovenous fistula or graft is regarded as a critical priority by patients and health …

BACKGROUND: Hemodialysis vascular access failure occurs often and increases morbidity
for people on hemodialysis therapy. Antiplatelet agents may prevent hemodialysis vascular …

Background End‐stage renal disease (ESRD) patients often require either the formation of
an arteriovenous (AV) fistula or an AV interposition prosthetic shunt for haemodialysis …

Background Current Renal Association guidelines recommend the creation of an
arteriovenous fistula as the first choice for hemodialysis access, with artificial grafts kept in …

Background The benefits and risks of antiplatelet therapy for patients with chronic kidney
disease (CKD) remain controversial. We undertook a systematic review and meta-analysis …